Latest News Archive

Please select Category, Year, and then Month to display items

Research project examines variation between Sesotho, Setswana in Free State

10 September 2019 | Story Rulanzen Martin | Photo Rulanzen Martin

Lingustics — Delegates at the workshop were provided opportunities that many larger conferences do not offer.

The growing body of work examining microvariation in African languages prompted Dr Kristina Riedel and Dr Hannah Gibson, from the University of Essex and research fellow, to work on a research project, “Variation in Sesotho and Setswana as spoken in the Free State”, to document the dialectal variation in the languages as it is spoken in the province.

“Dr Gibson and I have a joint research project which is funded by a Newton British Academy mobility grant,” says Dr Riedel, Head of the Department of Linguistic and Language Practice at the University of the Free State (UFS).

The duo hosted a workshop on morphosyntactic microvariation (small structural differences that can be observed between closely related languages or dialects) on the UFS Bloemfontein Campus, as part of the Newton Fund research project.

Research focus on dialectal variation

Dr Riedel says there has been some linguistic work on both of these languages. “But for Sesotho, linguists have noted that there is no dialectal variation. This seems hard to believe given the size of the population who speak the language,” she says.

They are looking at speakers in the Free State province for differences in both languages. Speakers themselves also report awareness of dialectal differences and variation between different regions. “We’re also interested in whether they have influenced each other – particularly in places where people speak both of these languages on a day-to-day basis, such as Thaba ’Nchu and Bloemfontein,” Dr Riedel says.

Dr Riedel believes that in the context of an African university it is important to contribute to the development, teaching and support of African languages. “Research on African languages can play an important part of this picture. Furthering our knowledge and understanding of African languages from a linguistic perspective also contributes to our understanding of the world’s languages and linguistic diversity.”

Workshop creates space for training and skill sharing

The aim of the workshop was to bring together researchers, students and language practitioners to “provide them with some of the insights and training that is helpful when looking at morphosyntactic microvariation”, Dr Riedel says.

The workshop was conducted in two sets. At the first workshop the emphasis was on training and sharing of skills and the second part focused on more research-related presentations.

The workshop, which took place on 19 July 2019, was attended by delegates from numerous local institutions (Rhodes University, University of the Western Cape and Stellenbosch University) as well as universities in the rest of Africa including the University of Malawi, Dar es Salaam University College of Education and Makerere University in Uganda.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept